Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Amsidyl, m-AMSA
Amsacrine is an antineoplastic agent, specifically a topoisomerase II inhibitor, used to treat various forms of leukemia. It interferes with the enzyme topoisomerase II, which is essential for DNA replication and repair, ultimately leading to cell death. Amsacrine is typically administered intravenously and is often used in combination with other chemotherapy drugs.
Treatment of acute myeloid leukemia, especially relapsed or refractory cases.
Severe myelosuppression, including leukopenia, neutropenia, thrombocytopenia, and anemia. Cardiac toxicity, including arrhythmias and cardiomyopathy.
Outcome:
Increased myelosuppression
Mechanism:
Additive bone marrow suppression
Outcome:
Increased risk of allopurinol toxicity
Mechanism:
Reduced allopurinol clearance
Outcome:
Reduced amsacrine absorption
Mechanism:
Chelation or altered pH
Most likely new formulation: Liposomal amsacrine for improved efficacy and reduced toxicity (Year: 2028, 30% confidence)
Based on historical usage patterns and emerging therapies, there is a low ( <5%) likelihood of a significant change in amsacrine's regulatory status in the next 5 years.
Antineoplastic Agent, Topoisomerase II Inhibitor
Acridine Derivative